| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/06/2001 | US6197782 Therapy for sexual disorders |
| 03/06/2001 | US6197780 Administering an endothelin anatgonist |
| 03/06/2001 | US6197778 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 03/06/2001 | US6197773 N-acyl and N-aroyl aralkyl amides as serotonergic agents |
| 03/06/2001 | US6197772 1- (1,2-disubstituted piperidinyl) -4-substituted piperazine derivatives |
| 03/06/2001 | US6197769 Serotonine receptors antagonist; gastrointestinal disorders, antiarrhythmia agents; incontinence |
| 03/06/2001 | US6197758 Methods for supplying postgastrectomic mineral and methods for treating postgastrectomic syndrome |
| 03/06/2001 | US6197750 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 03/06/2001 | US6197746 Method of using secretin for treating autism |
| 03/06/2001 | US6197584 Antisense modulation of CD40 expression |
| 03/06/2001 | US6197581 Human adenylate cyclase and use therefor |
| 03/06/2001 | US6197580 Transcriptional regulation of the human β3-adrenergic receptor gene |
| 03/06/2001 | US6197571 Protein polysaccharide 0041 |
| 03/06/2001 | US6197541 Nucleic acid which codes for mammalian receptor having seven transmembrane domains; drug screening of anticoagulants and wound healing agents; diagnosis of cardiovascular disorders; treatment of restenosis and unstable angina |
| 03/06/2001 | US6197300 ftsZ |
| 03/06/2001 | US6197279 Methods of delivering oxygen with emulsions |
| 03/06/2001 | US6197069 Adrenomedullin receptor polynucleotides |
| 03/06/2001 | CA2132416C Use of transglutaminase inhibitor for the treatment of scar tissue |
| 03/06/2001 | CA2073673C Esters of 2-arylmethyl-1-naphthol derivatives as 5-lipoxygenase inhibitors |
| 03/06/2001 | CA2010635C Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| 03/01/2001 | WO2001014886A2 Inhibitors of binding between proteins and macromolecular ligands |
| 03/01/2001 | WO2001014584A2 Methods of identifying anti-viral agents |
| 03/01/2001 | WO2001014551A1 NOVEL bHLH TYPE TRANSCRIPTION FACTOR GENE DEC2 |
| 03/01/2001 | WO2001014542A1 A transmembrane trap for isolating membrane bound proteins |
| 03/01/2001 | WO2001014535A2 UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-β1,3-N-ACETYLGALACTOSAMINE-α-R/(GlcNAc to GalNAc) β1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3 |
| 03/01/2001 | WO2001014418A2 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF |
| 03/01/2001 | WO2001014415A2 Egfh2 genes and gene products |
| 03/01/2001 | WO2001014414A2 Human abc2 transporter and uses thereof |
| 03/01/2001 | WO2001014405A2 Methods of obtaining 2-methoxyestradiol of high purity |
| 03/01/2001 | WO2001014402A1 Antisense modulation of focal adhesion kinase expression |
| 03/01/2001 | WO2001014400A1 2'-o-acetamido modified monomers and oligomers |
| 03/01/2001 | WO2001014380A1 Isomeric fused pyrrolocarbazoles and isoindolones |
| 03/01/2001 | WO2001014375A1 Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives |
| 03/01/2001 | WO2001014372A2 Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent |
| 03/01/2001 | WO2001014371A1 N-heterocyclic derivatives as nos inhibitors |
| 03/01/2001 | WO2001014365A1 COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING bcl-2 FAMILY MEMBER PROTEINS |
| 03/01/2001 | WO2001014364A1 Fatty acid synthase inhibitors |
| 03/01/2001 | WO2001014363A1 Fatty acid synthase inhibitors |
| 03/01/2001 | WO2001014362A1 Fatty acid synthase inhibitors |
| 03/01/2001 | WO2001014360A2 Benzopyrans and benzothiopyrans as rar selective retinoid agonists |
| 03/01/2001 | WO2001014358A2 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans |
| 03/01/2001 | WO2001014352A1 Substituted benzylthiazolidine-2,4-dione derivatives |
| 03/01/2001 | WO2001014351A1 Substituted benzylthiazolidine-2,4-dione derivatives |
| 03/01/2001 | WO2001014350A1 Substituted benzylthiazolidine-2,4-dione derivatives |
| 03/01/2001 | WO2001014349A1 Substituted benzylthiazolidine-2,4-dione derivatives |
| 03/01/2001 | WO2001014347A1 Benzoxazine and benzothiazine derivatives and the use thereof in medicaments |
| 03/01/2001 | WO2001014342A1 Aminocarbonyl-substituted benzimidazole derivatives, method for producing same and the use thereof as medicaments |
| 03/01/2001 | WO2001014337A1 αvβ3 INTEGRIN INHIBITORS |
| 03/01/2001 | WO2001014333A1 Substituted piperidine compounds useful as modulators of chemokine receptor activity |
| 03/01/2001 | WO2001014332A1 Piperidine alcohols |
| 03/01/2001 | WO2001014320A1 Compounds that inhibit tryptase activity |
| 03/01/2001 | WO2001014318A2 New effectors of dipeptidyl peptidase iv for topical use |
| 03/01/2001 | WO2001013957A2 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| 03/01/2001 | WO2001013953A2 Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist |
| 03/01/2001 | WO2001013936A1 Induced regeneration and repair of damaged neurons and nerve axon myelin |
| 03/01/2001 | WO2001013934A1 Peptide and peptide analogues for the treatment and prevention of diabetes |
| 03/01/2001 | WO2001013925A1 Remedies |
| 03/01/2001 | WO2001013917A1 Npy antagonists: spiroisoquinolinone derivatives |
| 03/01/2001 | WO2001013916A1 Drugs inhibiting cell death |
| 03/01/2001 | WO2001013903A2 Treatment of restless leg syndrome with a combination of clonidine and opioid |
| 03/01/2001 | WO2001013901A2 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress |
| 03/01/2001 | WO2001013900A2 Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds |
| 03/01/2001 | WO2001013878A1 Use of bacterial extracts of the pseudomonadaceae family as cosmetic agents |
| 03/01/2001 | WO2001013865A1 Pharmaceutical compositions and methods for reducing the appearance of cellulite |
| 03/01/2001 | WO2001013739A1 Growth promoting compositions for mammals and method of promoting the growth of mammals by using the same |
| 03/01/2001 | WO2000075365A3 COMPOUNDS AND METHODS TO ENHANCE rAAV TRANSDUCTION |
| 03/01/2001 | WO2000073449B1 Dna encoding snorf33 receptor |
| 03/01/2001 | WO2000071146A3 Glutathione reductase for therapy and prophylaxis of aids |
| 03/01/2001 | WO2000068223A8 Ureas and their use as cell adhesion modulators |
| 03/01/2001 | WO2000068209A3 1,5-benzodiazepine derivatives as cck-a receptor agonists |
| 03/01/2001 | WO2000064422A3 Novel treatment of neurotraumatic conditions with raf inhibitor |
| 03/01/2001 | WO2000061141A3 Methods and compositions for enhancing delivery of therapeutic agents to tissues |
| 03/01/2001 | WO2000023037A8 Two chamber cartridge for atomizers |
| 03/01/2001 | WO1999043314A9 Farnesyl-protein transferase inhibitors |
| 03/01/2001 | WO1998029107A3 Poly(diallylamine)-based bile acid sequestrants |
| 03/01/2001 | DE19941115A1 Neue Benzoxazin- und Bezothiazin-Derivate und deren Verwendung in Arzneimitteln New benzoxazine and Bezothiazin derivatives and their use in medicaments |
| 03/01/2001 | DE19940130A1 Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung New effectors of dipeptidyl peptidase IV for topical use |
| 03/01/2001 | DE19939980A1 Inhibitoren des Integrins alphavbeta¶3¶ Inhibitors of integrin alphavbeta¶3¶ |
| 03/01/2001 | DE19939910A1 Neue Verbindungen, die Tryptase-Aktivität hemmen Novel compounds that inhibit tryptase activity |
| 03/01/2001 | DE10036854A1 Neue kristalline Form von 6-Hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophenhydrochlorid New crystalline form of 6-hydroxy-3- (4- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride |
| 03/01/2001 | CA2715683A1 Synergistic combination |
| 03/01/2001 | CA2384197A1 Fatty acid synthase inhibitors |
| 03/01/2001 | CA2383559A1 Inhibitors of binding between proteins and macromolecular ligands |
| 03/01/2001 | CA2383371A1 P193 proteins and nucleic acids, and uses thereof |
| 03/01/2001 | CA2383252A1 Treatment of cardiovascular related pathologies |
| 03/01/2001 | CA2383063A1 Human abc2 transporter and uses thereof |
| 03/01/2001 | CA2383057A1 Induced regeneration and repair of damaged neurons and nerve axon myelin |
| 03/01/2001 | CA2382648A1 Drug treatment for restless leg syndrome |
| 03/01/2001 | CA2382582A1 Substituted benzylthiazolidine-2,4-dione derivatives |
| 03/01/2001 | CA2382574A1 Substituted benzylthiazolidine-2,4-dione derivatives |
| 03/01/2001 | CA2382561A1 Inhibitors of integrin .alpha.v.beta.3 |
| 03/01/2001 | CA2382527A1 Rar selective retinoid agonists |
| 03/01/2001 | CA2382430A1 Use of bacterial extracts of the pseudomonadaceae family as cosmetic agents |
| 03/01/2001 | CA2382295A1 Piperidine alcohols |
| 03/01/2001 | CA2382101A1 A transmembrane trap for isolating membrane bound proteins |
| 03/01/2001 | CA2382016A1 Composition for growth promotion of mammals and method for growth promotion of mammals using the same |
| 03/01/2001 | CA2381425A1 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| 03/01/2001 | CA2381111A1 Npy antagonists: spiroisoquinolinone derivatives |
| 03/01/2001 | CA2381096A1 Compounds that inhibit tryptase activity |
| 03/01/2001 | CA2379875A1 New effectors of dipeptidyl peptidase iv for topical use |